@middeldorps.bsky.social
Head Department of Internal Medicine at Radboudumc, Nijmegen 🇳🇱. Professor fighting venous thromboembolism. Pregnancy, thrombosis, thrombophilia. Elected council member of ISTH. Feminist with ❤️ husband & 3 sons. 🚴🏼♀️🏃🏻♀️. #Hemesky #Thrombosky
Congratulations to @isth.org Councilor @middeldorps.bsky.social on being named & delivering the 2025 Sol Sherry Disting. Lecture in Thrombosis @ the recent @americanheart.bsky.social Scientific Sessions recognizing her role as a foremost clinician & researcher in the field of CV disease & stroke!
📰 Check it out! The @ash.hematology.org and ISTH Updated Guidelines on the Treatment of Pediatric VTE are featured in Hematology Advisor.
Don’t miss this spotlight on our collaborative effort!
📖 Read the full feature: www.hematologyadvisor.com/news/pediatr...
#PediatricVTE #Hematology #ISTH
What an inspiring #ISTH2025!
It was wonderful to host the global #thrombosis & #hemostasis community in DC.
From the latest science & innovations to networking & building new collabs - it had it all!
Look out for recordings & other post- @isth.org congress updates.
Goodbye & see you @ #ISTH2026!
#ISTH2025
Marc Rodger highlighting the #Highlow study and providing guidance on how to implement the results 👌🏼
Now my favourite topic presented eloquently by prof Marc Rodger.
Answering all the questions needed for providing well-informed information to your patients.
Put the #LMWH needles away in patients with placenta-mediated complications in inherited #thrombophilia!
#AFFIRM #ALIFE2
#ISTH2025
It took 7 years to recruit 51 patients for the IMPACT single-arm study on certiluzomab on top of LMWH-aspirin shows adverse outcome in 20% which is lower than non-contemporary controls.
#ISTH2025
More on pregnancy and #APS, now from obstetric perspective.
Only 1% of recurrent miscarriage patients had APS antibodies, similar to controls.
#ISTH2025
Implementation matters!
A guideline-driven VTE prevention program (Vermont Model) led to ~60% of high-risk cancer patients receiving prophylactic anticoagulation—resulting in a 60% reduction in VTE and 56% reduction in death. #ISTH2025 #VTEprevention 🩸
@marycushmanmd.bsky.social
Why do we have so little data on pregnancy and thrombotic outcomes in #APS??
Well-illustrated by State-of-the-Art lecture by dr Karen Breen.
We MUST do better!
#ISTH2025
Not yet published in full!
Wow that’s pretty high!
Thanks! I couldn’t make it to the presentation. So, no capping at a maximum dose was applied?
📣 ARIVA Trial at #ISTH2025:
🧪 First RCT on antithrombotic therapy post-venous stenting for PTS
🔵 6-month primary patency rate was higher than expected
💊 No added benefit of aspirin + rivaroxaban vs. rivaroxaban alone
www.ahajournals.org/doi/10.1161/...
The apicat trial did study apixaban dose reduction VS full dose. That study makes me very comfortable using apixaban in this setting
Hope you feel better!
In my experience, young people who don’t take any other meds and are in for the really long term sec prevention, have difficulty being adherent to the evening dose of apixaban
Meta-analysis on GLP-1RA (vs. placebo) and VTE:
🔹 PE rates significantly lower 📉
🔹 VTE rates lower but not statistically significant
🔹 No difference in DVT
🔹 Study design matters: RCTs vs. observational data
Accepted for publication in JTH!
#ISTH2025 #VTE #GLP1RA #Thrombosis
@jthjournal.bsky.social
It’s really worth stopping by our @isth.org booth and get inspired for next year’s meeting in….. Paris!
#ISTH2025
What started as strong Mendelian observations, has now evolved to a strongly polygenenic etiology of #VTE. Inside and outside the coagulation cascade.
#ISTH2025
There is more to established #thrombophilia defects in understanding the genetics of venous thromboembolism #VTE.
Plenary lecture by Prof Pierre Morange
#ISTH2025
This was observed during the first 3 months after acute VTE. I’d like to keep the rivaroxaban option for extended treatment for patients who value the once daily regimen and are at low bleeding risk.
Tips for asking ?s as moderator #ISTH2025
Clinical talk: what future directions do you see this work taking?
Basic science: how do you envision this translating to the clinic?
Next level pro tip: contact author beforehand to see what they didn’t have time to present that they’d like you to ask
Adjust-DVT study. Only 5% of patients with suspected #DVT had an age-adjusted d-dimer that omits the need for compression ultrasound.
I don’t think it is worth it. What do you think?
#ISTH2025
This is why diagnosing, treating and investigating #APS is so complicated.
Massive differences in classification between Sydney 2006 and ACR/EULAR 2023. Only 40% of patients fulfilled the new criteria.
What are the implications for future research?
#ISTH2025
The effects of andexanet on enoxaparin are in line with effects on oral factorXa inhibitors.
Great presentation by PhD student Thijs van Haaps
#ISTH2025
Excellent points ⬇️
Exclusion of pregnant people from trials leads to paradoxical effects!
#ISTH2025
State-of-the-Art talk bij de Luuk Scheres
Despite hormone use being the most prevalent and important risk factor for #VTE in women <50, there is huge underrepresentation of risk models and funding.
Food for thought and action 💪🏼
#ISTH2025
There is still taboo about discussing menstruation 🩸
There are differences between assessment of abnormal uterine bleeding between professional societies.
This is important to realisme and underscores the need to collaborate multidisciplinary.
Dr Roseline d’Oiron
#ISTH2025
Even if you are not a pediatrician, you can learn so much. Beautiful slides on thrombolysis 🤩
Dr Irene Klaassen #ISTH2025